That seems to be the favorite interpretation. We need to see what data they present that favors it (ie % survival of the treated cells, number of initial cells,

That seems to be the favorite interpretation. We need to see what data they present that favors it (ie % survival of the treated cells, number of initial cells, % mutants at that location detected in control cells). Also, this is kind of weird, because they say it is non-randomized: Study Design: Allocation: Non-Randomized Endpoint Classification: Safety Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment But later it says: Progression free survival - PFS [ Time Frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to average 10 months ] [ Designated as safety issue: No ] Overall Survival - OS [ Time Frame: The time from randomization to death from any cause, assessed up to 2 years ] [ Designated as safety issue: No ] So is the treatment randomized or not? The info on that site may not be reliable... maybe it makes sense somehow though.